Beckman Coulter Announces Second Quarter 20...(tent errors insummarizing these amounts....)

Date:7/25/2008

tent errors in summarizing these amounts. These immaterial errors resulted in an overstatement of cash flows provided by operating activities, with an equal overstatement of cash flows used in investing activities, but had no effect on our Condensed Consolidated Balance Sheets and Condensed Consolidated Statements of Earnings as presented in our Form 10-Q for the quarter and six months ended June 30, 2007. The amounts presented in the Condensed Consolidated Statement of Cash Flows for the six months ended June 30, 2007, have been restated to correct these immaterial errors, as set forth in the following table:

Previously

Reported restated

Depreciation and amortization $99.9 $95.7

Change in inventories (28.7) (33.3)

Change in long-term lease receivables 6.2 4.4

Change in other (7.9) (6.4)

Net cash provided by operating activities 197.0 187.9

Additions to property, plant and equipment (147.5) (138.4)

Net cash used in investing activities (158.3) (149.2)

Change in Accounting for Convertible Debt Securities

In May 2008, the FASB issued FSP No. APB 14-1 "Accounting for Convertible Debt Instruments That May Be Settled in Cash upon Conversion (Including Partial Cash Settlement)" ("FSP APB 14-1")." Under this standard, convertible debt securities that may be settled in cash (or other assets), including partial cash settlement, would be separated into a debt and equity component. This change in methodology, which will become effective for us as of the beginning of 2009, will be applied retrospectively to previously issued convertible debt instruments as well as to new instruments. The adoption of this
'/>"/>

SOURCE Beckman Coulter, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28
Related biology technology :

1. Beckman Coulter Announces Second Quarter 2008 Earnings to be Released on Friday, July 25, 2008, Before Market Opens
2. Upcoming Beckman Coulter Investor Events Second Half of 2008
3. Beckman Coulter to Present at Upcoming Healthcare Conferences
4. Beckman Coulter Announces First Quarter 2008 Results
5. Beckman Coulter Acquires Rights to Hepatitis C Virus
6. Beckman Coulter Declares Quarterly Dividend Payout of $0.17 Per Share
7. The Immune Tolerance Institute Announces Collaboration with Beckman Coulter Establishing a Multiplatform Immunophenotyping/Immunogenotyping Laboratory
8. Beckman Coulter to Present at the 2008 Bear Stearns London Healthcare Conference
9. Beckman Coulter Releases the High-Volume UniCel(R) DxC 880i Integrated Work Cell
10. AcroMetrix Signs Development and Supply Agreement With Beckman Coulter Inc. for Molecular Quality Control Standards
11. Beckman Coulter to Present at the JPMorgan Healthcare Conference